In clinical studies, MSCs are shown to decrease the plasma levels of BAFF in patients with cGVHD or refractory rheumatoid arthritis (RA), accompanied with regulating the activity of B cells and alteration in B cell subpopulation (128, 129). The gene discussed is TNFSF13B; the disease is rheumatoid arthritis.